Patents by Inventor Gaoping Li

Gaoping Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds, compositions and methods for reducing lipid levels
    Patent number: 8710071
    Abstract: The present technology relates to compounds of Formulas (V) and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated protein kinase.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: April 29, 2014
    Assignee: CVI Pharmaceuticals Limited
    Inventors: Haiyan Liu, Gaoping Li, Junbo Wang, Jingwen Liu
  • COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS
    Publication number: 20120004223
    Abstract: The present technology relates to compounds of Formulas (V) and (VI) and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated protein kinase.
    Type: Application
    Filed: December 22, 2009
    Publication date: January 5, 2012
    Inventors: Haiyan Liu, Gaoping Li, Junbo Wang, Jingwen Liu
  • Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same
    Publication number: 20110009628
    Abstract: The present technology relates to compounds of Formulas I-VI and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also increase HDL-C, lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated protein kinase.
    Type: Application
    Filed: July 8, 2010
    Publication date: January 13, 2011
    Inventors: Haiyan Liu, Gaoping Li, Junbo Wang, Jingwen Liu